Dynamics of FABP4 and CTRP3 biomarkers in patients with acute myocardial infarction and type 2 diabetes mellitus

Authors

DOI:

https://doi.org/10.15587/2519-4798.2022.257003

Keywords:

markers, adipokine metabolism, acute myocardial infarction, adverse course, diabetes mellitus

Abstract

The aim of the work was to study the characteristics of adipokine metabolism based on the analysis of fatty acid binding protein 4 (FABP4) and C1q/tumour necrosis factor-related protein-3 (CTRP3) levels and their dynamics in non-diabetic and diabetic patients with cardiovascular (CV) complications of acute myocardial infarction (AMI).

Materials and methods. The study was carried out between 2018 and 2020 and involved 134 AMI patients with or without type 2 diabetes mellitus (DM) aged 59.00 [52.75; 66.00] years. The control group consisted of 20 healthy individuals with the mean age of 56.50 [48.50; 61.75] years. The serum levels of FABP4 and CTRP3 were measured by enzyme-linked immunosorbent assay on days 1 and 10 of hospital stay.

Results. The mean levels of FABP4 were elevated on day 1 in AMI patients with type 2 DM (group II) compared to those in AMI patients (group I) and the control individuals (p<0.05). The FABP4 concentrations on day 10 were 7.68 [6.42; 8.42] ng/ml and 8.31 [6.92; 9.63] ng/ml (p<0.05) in groups I and II, respectively. The CTRP3 levels were lower in group II on day 1 as compared to those in group I and the control group patients (p<0.001). After 10 days, the levels of CTRP3 were 287.56 [271.48; 300.58] ng/ml and 262.01 [225.32; 288.84] ng/ml) (p<0.001) in groups I and II, respectively. In the presence of early AMI complications in diabetic patients, the levels of FABP4 remained elevated on day 10, and the levels of CTRP3 were low compared to those in diabetic patients without AMI complications (p<0.05).

Conclusions. The characteristics of adipokine metabolism in AMI patients have been revealed: the worsened imbalance in adipokine metabolism in type 2 DM due to the difference in FABP4 and CTRP3 levels. Special mention should be made of severely deteriorated adipokine metabolism in diabetic patients with CV complications

Author Biography

Mariia Koteliukh, Kharkiv National Medical University

PhD

Department of Internal Medicine No. 2, Clinical Immunology and Allergology named after academician L. T. Malaya

References

  1. WHO Newsletter: 10 leading causes of death in the world (2020). Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
  2. Standl, E., Khunti, K., Hansen, T. B., Schnell, O. (2019). The global epidemics of diabetes in the 21st century: Current situation and perspectives. European journal of preventive cardiology, 26 (2), 7–14. doi: http://doi.org/10.1177/2047487319881021
  3. WHO Newsletter: Diabetes. November 10, 2021. https://www.who.int/ru/news-room/fact-sheets/detail/diabetes
  4. Khalid, S. H., Liaqat, I., Mallhi, T. H., Khan, A. H., Ahmad, J., Khan, Y. H. (2020). Impact of diabetes mellitus on clinico-laboratory characteristics and in-hospital clinical outcomes among patients with myocardial infarction. The Journal of the Pakistan Medical Association, 70 (12 (B)), 2376–2382. doi: https://doi.org/10.47391/JPMA.370
  5. Obokata, M., Iso, T., Ohyama, Y., Sunaga, H., Kawaguchi, T., Matsui, H. et. al. (2018). Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction. European heart journal. Acute cardiovascular care, 7 (6), 561–569. doi: http://doi.org/10.1177/2048872616683635
  6. Wu, D., Lei, H., Wang, J. Y., Zhang, C. L., Feng, H., Fu, F. Y. et al. (2015). CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation. Journal of molecular medicine, 93 (12), 1311–1325. doi: http://doi.org/10.1007/s00109-015-1309-8
  7. Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H. et al. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal, 39 (2), 119–177. doi: http://doi.org/10.1093/eurheartj/ehx393
  8. Online version of IDF Diabetes Atlas: Nineth edition, 2019. https://www.diabetesatlas.org/en/
  9. Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G. et. al. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61 (12), 2461–2498. doi: http://doi.org/10.1007/s00125-018-4729-5
  10. Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V. et. al. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European heart journal, 41 (2), 255–323. doi: http://doi.org/10.1093/eurheartj/ehz486
  11. Simek, S., Motovska, Z., Hlinomaz, O., Kala, P., Hromadka, M., Knot, J. et. al. (2020). The effect of diabetes on prognosis following myocardial infarction treated with primary angioplasty and potent antiplatelet therapy. Journal of clinical medicine, 9 (8), 2555. doi: http://doi.org/10.3390/jcm9082555
  12. Reiser, H., Klingenberg, R., Hof, D., Cooksley-Decasper, S., Fuchs, N., Akhmedov, A. et al. (2015). Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arteriosclerosis, thrombosis, and vascular biology, 35 (8), 1872–1879. doi: http://doi.org/10.1161/atvbaha.115.305365
  13. Liu, G., Ding, M., Chiuve, S. E., Rimm, E. B., Franks, P. W., Meigs, J. B. et. al. (2016). Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study. Arteriosclerosis, thrombosis, and vascular biology, 36 (11), 2259–2267. doi: http://doi.org/10.1161/atvbaha.116.308320
  14. Liu, M., Zhou, M., Bao, Y., Xu, Z., Li, H., Zhang, H. et. al. (2013). Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clinical science, 124 (2), 115–122. doi: http://doi.org/10.1042/cs20120004
  15. Liang, W., Ye, D. D. (2019). The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus. Cytokine & growth factor reviews, 48, 32–39. doi: http://doi.org/10.1016/j.cytogfr.2019.06.002
  16. Choi, K. M., Hwang, S. Y., Hong, H. C., Choi, H. Y., Yoo, H. J., Youn, B. S. et. al. (2014). Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris. Cardiovascular diabetology, 13 (1). doi: https://doi.org/10.1186/1475-2840-13-14
  17. Chen, L., Liu, S., Xu, W., Zhang, Y., Bai, J., Li, L., et al. (2020). Association of plasma C1q/TNF-related protein 3 (CTRP3) in patients with atrial fibrillation. Mediators of inflammation, 2020, 8873152. doi: http://doi.org/10.1155/2020/8873152
  18. Yildirim, A., Sumbul, H. E., Koca, H., Kucukosmanoglu, M., Kemal Icen, Y., Koc, M. (2021). Complement C1q/tumor necrosis factor-related protein-3 (CTRP3) is significantly decreased in patients with heart failure and closely related with ventricular tachycardia. Acta Cardiologica Sinica, 37 (3), 278–285. doi: https://doi.org/10.6515/ACS.202105_37(3).20201019B

Downloads

Published

2022-05-31

How to Cite

Koteliukh, M. (2022). Dynamics of FABP4 and CTRP3 biomarkers in patients with acute myocardial infarction and type 2 diabetes mellitus. ScienceRise: Medical Science, (3(48), 4–8. https://doi.org/10.15587/2519-4798.2022.257003

Issue

No. 3(48) (2022)

Section

Medical Science

License

Copyright (c) 2022 Mariia Koteliukh

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.